Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark S Levenson

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Clinical Trials (London, England)|February 18, 2020
Regulatory-grade clinical trial design using real-world dataMark S Levenson
Journal of Biopharmaceutical Statistics|January 22, 2013
Regulatory issues of propensity score methodology application to drug and device safety studiesMark S Levenson, Lilly Q Yue
Journal of Research of the National Institute of Standards and Technology|November 21, 2017
Performance Measures for Geometric Fitting in the NIST Algorithm Testing and Evaluation Program for Coordinate Measurement SystemsTheodore H Hopp, Mark S Levenson
Statistics in Biopharmaceutical Research|June 30, 2021
Comment on "Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic"Sylva H Collins, Mark S Levenson
The New England Journal of Medicine|July 1, 2011
Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthmaBadrul A Chowdhury, Sally M Seymour, Mark S Levenson
Pediatrics|October 26, 2011
Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonistsAnn W McMahon, Mark S Levenson, Bradley W McEvoy, et al.
Journal of Biopharmaceutical Statistics|September 16, 2015
The role of quantitative safety evaluation in regulatory decision making of drugsAloka G Chakravarty, Rima Izem, Stephine Keeton, et al.
Pharmacoepidemiology and Drug Safety|November 29, 2013
Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research DatalinkEsther H Zhou, Kate Gelperin, Mark S Levenson, et al.
Pharmacoepidemiology and Drug Safety|August 24, 2017
Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the communityKunthel By, Jana K McAninch, Stephine L Keeton, et al.
Pharmacoepidemiology and Drug Safety|June 5, 2013
Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRDAndrea V Margulis, Adel Abou-Ali, Marian M Strazzeri, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Clinical Trials (London, England)|February 18, 2020
Regulatory-grade clinical trial design using real-world dataMark S Levenson
Journal of Biopharmaceutical Statistics|January 22, 2013
Regulatory issues of propensity score methodology application to drug and device safety studiesMark S Levenson, Lilly Q Yue
Journal of Research of the National Institute of Standards and Technology|November 21, 2017
Performance Measures for Geometric Fitting in the NIST Algorithm Testing and Evaluation Program for Coordinate Measurement SystemsTheodore H Hopp, Mark S Levenson
Statistics in Biopharmaceutical Research|June 30, 2021
Comment on "Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 Pandemic"Sylva H Collins, Mark S Levenson
The New England Journal of Medicine|July 1, 2011
Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthmaBadrul A Chowdhury, Sally M Seymour, Mark S Levenson
Pediatrics|October 26, 2011
Age and risks of FDA-approved long-acting β₂-adrenergic receptor agonistsAnn W McMahon, Mark S Levenson, Bradley W McEvoy, et al.
Journal of Biopharmaceutical Statistics|September 16, 2015
The role of quantitative safety evaluation in regulatory decision making of drugsAloka G Chakravarty, Rima Izem, Stephine Keeton, et al.
Pharmacoepidemiology and Drug Safety|November 29, 2013
Risk of acute myocardial infarction, stroke, or death in patients initiating olmesartan or other angiotensin receptor blockers - a cohort study using the Clinical Practice Research DatalinkEsther H Zhou, Kate Gelperin, Mark S Levenson, et al.
Pharmacoepidemiology and Drug Safety|August 24, 2017
Important statistical considerations in the evaluation of post-market studies to assess whether opioids with abuse-deterrent properties result in reduced abuse in the communityKunthel By, Jana K McAninch, Stephine L Keeton, et al.
Pharmacoepidemiology and Drug Safety|June 5, 2013
Use of selective serotonin reuptake inhibitors in pregnancy and cardiac malformations: a propensity-score matched cohort in CPRDAndrea V Margulis, Adel Abou-Ali, Marian M Strazzeri, et al.
Pageof 2